Abstract:Background Smoking is a well-identified risk factor for recurrent cardiovascular (CV) events in patients with stable coronary artery disease (CAD). However, smoking status is not binary, and there is a wide diversity of smoking habits trajectories within this population, with different consequences on residual CV risk. Purpose To better understand how smoking status evolves in patients with CAD, and how it is associated with subsequent CV events. Methods We analysed the CLARIFY registry, which included 32,378 patients with CAD. We defined groups according to smoking status at inclusion in the registry: never, former and active smokers. For former smokers, we assessed the timing of definitive smoking discontinuation and its relationship with subsequent CV events. For active smokers, we investigated the association between smoking reduction or discontinuation in active smokers with outcomes. Our primary endpoint was the occurrence of MACE defined by CV death or myocardial infarction (MI) during the 5-year follow-up period adjusted on known predictors for MACE in CAD patients. Results At inclusion, 13,366 (41.3%) patients had never smoked, 14,973 (46.2%) were former smokers, and 4,039 (12.5%) were current smokers, after an average of 6.5 (±6.3) years following CAD diagnosis. In former smokers that were smoking at the time of CAD diagnosis, 72.8% definitively discontinued smoking within the first year following diagnosis, while only 27.2% quit in subsequent years. Each additional year of active smoking after CAD diagnosis increased the risk of MACE (adjusted HR [aHR] 1.08, 95% CI 1.04-1.12 per year). However, regardless of the duration of smoking cessation, former smokers did not return to the cardiovascular risk levels observed in individuals who never smoked (figure). In active smokers at inclusion, smoking cessation was associated with improved CV outcomes, irrespective of the timing of cessation during follow-up (aHR 0.56, 95% CI 0.42-0.76, p < 0.001). Among active smokers, 25.7% reduced their quantity smoked within the first year of follow-up without quitting, but this did not significantly reduce the rate of CV death and MI (aHR 0.96, 95% CI 0.74-1.26, p = 0.78) compared to other active smokers. Conclusion In active smokers diagnosed with CAD, the vast majority of definite quitters cease smoking within the first year of CAD diagnosis. Each subsequent year of active smoking adversely affects CV outcomes. Smoking cessation at any time significantly reduces the risk of CV death or recurrent MI compared to persistent active smokers, although CV risk of former smokers does not decrease to the levels observed in never-smokers. Finally, smoking quantity reduction is not enough to reduce CV risk in this population. These findings underscore the critical importance of timely interventions for smokers diagnosed with CAD, and emphasize that when it comes to smoking cessation, sooner is better, but it is never too late.

Impact of smoking cessation and smoking interventions in patients with coronary heart disease

Impact of Smoking on All-Cause Mortality and Cardiovascular Events in Patients after Coronary Revascularization with a Percutaneous Coronary Intervention or Coronary Artery Bypass Graft: a Systematic Review and Meta-Analysis

Smoking behaviour in European patients with established coronary heart disease

Smoking status on outcomes after percutaneous coronary intervention.

Smoking and risk for morbidity and mortality in patients who undergoes coronary artery bypass grafting

Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium

Smoking cessation after acute myocardial infarction: a Swiss-wide cohort study

Smoking Cessation and Short- and Longer-Term Mortality

The association between smoking and long-term outcomes after non–ST-segment elevation myocardial infarction in older patients

Trajectories in smoking habits and outcomes in patients with stable coronary artery disease

Effectiveness and Safety of Platelet ADP -P2Y12 Receptor Inhibitors Influenced by Smoking Status: A Systematic Review and Meta-Analysis.

Impact of Smoking Cessation Duration on Lung Cancer Mortality: A Systematic Review and Meta-Analysis

Association Between Initiation, Intensity, and Cessation of Smoking and Mortality Risk in Patients With Cardiovascular Disease: A Cohort Study

Smoking and sudden cardiac death in patients with previous coronary artery disease

Abstract 14706: the Impact of Smoking on Short- and Long-Term Outcomes in NSTEMI Results from 38,628 Patients from the CRUSADE Registry

[The Impact of Cigarette Cessation Intervention on Mental State of Patients with Coronary Heart Disease].

Smoking, Smoking Cessation, and Survival after Cancer Diagnosis in 128,423 Patients Across Cancer Types

[Smoking Cessation Rate in Cardiovascular Patients after Percutaneous Coronary Intervention].

Smoking status and the effect of smoking cessation intervention in hospitalized patients with cardiocerebrovascular or diabetic diseases

P1180 Smoking behaviour and changes after diagnosis in patients with Crohn's disease in a tertiary referral hospital: A retrospective explorative study

Impacts of smoking status on the clinical outcomes of coronary non-target lesions in patients with coronary heart disease: a single-center angiographic study